On April 3, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported that it will present new data on Arginase 1 Deficiency patients at the 2018 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics (ACMG) in Charlotte, North Carolina on Thursday, April 12 (Press release, Aeglea BioTherapeutics, APR 3, 2018, View Source [SID1234525152]). The new data will include additional clinical insights on short-term treatment with repeat doses of pegzilarginase, including baseline standardized assessments of neuromotor function. The Company will conduct a clinical update conference call at 8:30 a.m. ET on April 12.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Weekly Pegzilarginase Produces Marked and Sustained Reductions in Guanidino Compounds in Adults with Arginase 1 Deficiency: Early Phase 1/2 Results

Presenting Author: Roberto Zori, M.D., University of Florida, Gainesville, FL

Poster Number: 803

Presentation Date and Time: Thursday, April 12, 10:00 a.m. to 11:30 a.m. ET

An electronic version of the presentation will be available for download from the Presentations & Events section of the Company’s investor relations website beginning on the day of the their presentation at the 2018 ACMG Annual Clinical Genetics Meeting.

Conference Call & Webcast Details
Aeglea will hold a clinical update conference call on Thursday, April 12, 2018 at 8:30 a.m. ET. To access the live conference call via phone, please dial 1-877-709-8155 (toll free) within the United States, or 1-201-689-8881 internationally. A replay of the call will be available through April 19, 2018 by dialing 1-877-660-6853 within the United States or 1-201-612-7415 internationally. The conference ID is 13678293.

To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.

About Pegzilarginase (AEB1102) in Arginase 1 Deficiency
Pegzilarginase is an enhanced human arginase that enzymatically degrades the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency, a debilitating urea cycle disorder caused by deficiency of a key arginine metabolizing enzyme that leads to severe and progressive hyperargininemia-related neurological abnormalities, hyperammonemia and early mortality. Pegzilarginase is intended for use as an enzyme replacement therapy in patients to reduce elevated blood arginine levels. The Company’s Phase 1 data demonstrated that pegzilarginase reduced blood arginine levels into the normal range, supporting its mechanism of action.

On April 3, 2018 Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, reported that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on Monday, April 9, 2018 at 11:30 a.m. CEST (Press release, Aptose Biosciences, APR 3, 2018, View Source [SID1234525154]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Time: 11:30 a.m. CEST
Date: Monday, April 9, 2018
Location: Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco
Live webcast: View Source
The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.

On April 3, 2018 AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) reported that the European Medicines Agency has validated for review the Marketing Authorisation Application (MAA) for Lynparza (olaparib) for use in patients with deleterious or suspected deleterious BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting (Press release, AstraZeneca, APR 3, 2018, View Source [SID1234525155]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is the first regulatory submission for a poly ADP-ribose polymerase (PARP) inhibitor in breast cancer in Europe. If approved, the identification of a patient’s BRCA status could become a critical step in the management of their disease alongside current consideration of their hormone receptor and HER2 status. The MAA includes data from the randomised, open-label, Phase III OlympiAD trial, which investigated Lynparza versus chemotherapy (physician’s choice of capecitabine, eribulin or vinorelbine). In the trial, Lynparza significantly prolonged progression-free survival compared with chemotherapy and reduced the risk of disease progression or death by 42% (HR 0.58; 95% CI 0.43-0.80; P=0.0009 median 7.0 vs. 4.2 months).

In January 2018, Lynparza was approved by the US Food and Drug Administration for use in the treatment of BRCA-mutated HER2-negative metastatic breast cancer, becoming the first PARP inhibitor to be approved beyond ovarian cancer. Lynparza is available in nearly 60 countries and has been used to treat more than 20,000 patients. AstraZeneca and MSD are working together to bring Lynparza to more patients across multiple cancers.

On April 3, 2018 Cancer Therapeutics CRC (CTX) is reported that appointment of Brett Carter as Chief Executive Officer (Press release, Cancer Therapeutics CRC, APR 3, 2018, View Source [SID1234525374]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Brett will succeed Dr Warwick Tong who has led CTX for the past 6 years and who will continue to provide services to the organisation in an advisory capacity. These changes reflect a transition plan agreed between Dr Tong and the CTX Board to evolve the organisation from a Federally supported Cooperative Research Centre (CRC) into an independent and self-sustainable organisation.

Commenting on the appointment, Dr Tony Evans Chair of CTX, said
:
"We are delighted to appoint Brett as Chief Executive Officer. Brett has excellent management skills, extensive industry experience and a track record of executing pharmaceutical deals, making him the ideal candidate to lead CTX moving forward. I would like to thank Warwick for his dedicated leadership of the organisation over the past 6 years. Warwick has made many contributions to CTX however I would like to specifically highlight his involvement in the PRMT5 licensing deal to Merck, which was one of Australia’s largest ever pre-clinical asset licensing deals."

Commenting on the appointment, Mr Carter, said:
"Cancer is Australia’s leading cause of pre-mature death and CTX’s unique and highly successful business model has resulted in the development of drug products that have the potential to provide cures for cancer patients. I am very excited to be taking over the leadership of an organisation with such a strong culture of innovation and delivery.
To move from a medical research hub to a global biotechnology leader, Australia needs organisations like CTX, that build the drug discovery and development capability necessary to translate the country’s world class medical research into clinical and commercial outcomes.

I want to thank Warwick for his mentorship over the past year and I look forward to working with the CTX team and stakeholders as we embark on the next stage of the organisation’s evolution."

On April 2, 2018 Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, reported that company management will give a corporate presentation at the H. C. Wainwright Annual Global Life Sciences Conference on Monday, April 9 at 10:40 a.m. CEST at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco (Press release, Tetraphase, APR 2, 2018, View Source [SID1234525121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Live audio webcasts of the presentation will be available on the company’s website at View Source Archived presentations will be available for 30 days.